Aalesund

• A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active convent … Pending
  2024-516723-14-00 6 Rheumatoid Arthritis
• Episodic CandClus2: A randomized, placebo-controlled, triple blind study of candesartan in adults with episodic cluster headache Pending
  2025-521470-34-00 5 episodic cluster headache
• Chronic CandClus2: A randomized, placebo-controlled, triple blind crossover study of candesartan in adults with chronic cluster headache Pending
  2025-521529-34-00 5 chronic cluster headache
• A randomized study in testicular cancer without metastasis, comparing two different types of chemotherapy used to reduce the risk of relapse Recruiting
  2024-518399-29-00 5 2024-12-27 Testicular cancer
• TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Recruiting
  2024-519917-72-00 5 2025-10-29 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind tr … Recruiting
  2024-517981-40-00 5 2025-06-06 Chronic Migraine
• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa … Recruiting
  2024-516030-35-00 5 2025-04-30 Multiple myeloma
• Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting
  2024-513779-42-02 4 2025-03-27 Cancer
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting
  2023-509994-22-00 5 2024-11-15 cutaneous malignant melanoma
• The Effect of Topical Tranexamic Acid on Postoperative Complications in Soft Tissue Plastic Surgery. A Multicenter Randomized Controlled Tri … Recruiting
  2023-510381-28-01 6 2024-09-18 Patients undergoing plastic surgical procedures with wounds that would
• Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcuta … Recruiting
  2023-510184-35-00 6 2024-08-20 Rheumatoid arthritis
• A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting
  2023-506150-21-00 4 2024-05-29 Celiac Disease
• The CORTAD study Recruiting
  2024-512888-31-00 11 2023-08-03 Primary adrenal insufficiency (PAI)
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 4 2023-06-23 Non-metastatic HER2-positive Breast Cancer
• Efficacy of Hyperbaric oxygen in addition to standard treatment for acute sudden deafness Recruiting
  2024-510798-84-00 10 2022-01-28 Idiopathic sudden sensorineural hearing loss (ISSNHL)
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 4 2021-04-01 Cancer
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 5 2019-01-08 Prostate Cancer
• The Norwegian Antibiotics for Pneumonia in Children (NAPIC) Study Recruiting
  2024-512001-39-01 6 2018-02-01 Lower respiratory tract infection
• RElapse from Mrd Negativity As iNdication for Treatment Ended recruitment
  2023-510215-18-00 10 2024-09-26 Multiple myeloma
• Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotacti … Ended recruitment
  2024-512439-54-01 4 2024-07-24 Non-small cell lung cancer (NSCLC)
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Showing 1–24 of 37 trials